MAIA Biotechnology, Inc. (MAIA) Stock Price

MAIAStock
$1.10−18.52%52W
Market Cap$67.92M
P/E—
PEG Ratio—
Div yield—
Beta0.28

MAIA Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-29.61%
Price vs S&P 500 (4W)-15.97%
VGM Score53.62

MAIA Earnings Surprise History

QuarterReport dateEPS estimateEPS actualSurprise
Q2 2026-$0.11-$0.13-18.18%(-$0.02)
Q1 2026-$0.18-$0.14+22.22%(+$0.04)
Q4 2025-$0.13-$0.14-5.23%(-$0.01)
Q3 2025-$0.19-$0.27-42.11%(-$0.08)
Q2 2025-$0.25-$0.17+32.84%(+$0.08)

MAIA Analyst Recommendations

Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.14
4.14
4.14
4.14

Industry Peers — Pharmaceuticals(574)

SymbolValue ScoreGrowth ScoreMomentum ScoreP/S Ratio (TTM)Revenue Growth TTM (YoY)Gross Margin (TTM)EPS Growth (5Y)Price
MAIAMAIA Biotechnology, Inc.
——C————$1.10
LLYEli Lilly & Co.DBA14.9x49.6%83.4%27.6%$1257.03
JNJJohnson & JohnsonDCB6.2x7.8%67.7%14.9%$255.56
ABBVABBVIE INC.DCA7.8x10.4%72.8%-2.9%$285.42
MRKMerck & Co., Inc.DCA5.4x4.6%77.3%21.2%$145.95
NVSNovartis AGCCB4.9x3.3%75.0%15.3%$150.62
AZNAstraZeneca PLCCBB4.3x8.6%81.3%21.9%$165.41
ABTAbbott LaboratoriesCCB3.9x8.1%56.8%8.2%$104.89
NVONovo-Nordisk A/SBCC3.5x5.6%80.7%20.7%$38.83
PFEPfizer Inc.CDA2.6x-0.2%74.7%-3.5%$29.58
VRTXVertex Pharmaceuticals IncDCB10.1x10.2%86.0%8.3%$499.74

About MAIA Biotechnology, Inc.

MAIA Biotechnology is a clinical-stage biopharmaceutical company developing THIO, an investigational drug candidate with dual anti-cancer mechanisms targeting telomeres and immune function. The lead program combines THIO with Regeneron's approved checkpoint inhibitor Libtayo (cemiplimab) to treat patients with advanced non-small cell lung cancer. The combination approach aims to enhance the immune system's ability to attack cancer cells.